Patents by Inventor Erik P. Johnson

Erik P. Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230143248
    Abstract: Described herein are methods for direct detection of microbial agent(s) in a polymicrobial sample, such as a biological sample from a human, without culturing the microbial agent(s). The direct detection can identify mixtures of bacteria and/or fungi in the sample. Also described are primer sequences and amplification techniques for performing the direct detection methods.
    Type: Application
    Filed: August 22, 2022
    Publication date: May 11, 2023
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Erik P. Johnson, Nik Isely, Jamie L. Platt, Martin Siaw, Ron M. Kagen, Dale A. Schwab
  • Patent number: 11421285
    Abstract: Described herein are methods for direct detection of microbial agent(s) in a polymicrobial sample, such as a biological sample from a human, without culturing the microbial agent(s). The direct detection can identify mixtures of bacteria and/or fungi in the sample. Also described are primer sequences and amplification techniques for performing the direct detection methods.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: August 23, 2022
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Nik Isely, Jamie L. Platt, Martin Siaw, Ron M. Kagen, Dale A. Schwab
  • Publication number: 20220145367
    Abstract: The present disclosure provides methods for determining whether a patient exhibiting pneumonia-like symptoms will benefit from treatment with therapeutic agents that inhibit Legionella sp. These methods are based on detecting Legionella sp. and/or Legionella pneumophila in a biological sample. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 12, 2022
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Erik P. Johnson
  • Publication number: 20210363569
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Application
    Filed: June 7, 2021
    Publication date: November 25, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Erik P. Johnson, Dale A. Schwab
  • Patent number: 11028450
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 8, 2021
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Dale A. Schwab
  • Publication number: 20210164022
    Abstract: The present invention provides methods and compositions for determining the presence and/or amount of pathogenic Leptospira in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting pathogenic Leptospira nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Leptospira assay.
    Type: Application
    Filed: January 21, 2021
    Publication date: June 3, 2021
    Applicant: Quest Diagnostics Investments LLC
    Inventor: Erik P. JOHNSON
  • Patent number: 10907218
    Abstract: The present invention provides methods and compositions for determining the presence and/or amount of pathogenic Leptospira in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting pathogenic Leptospira nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Leptospira assay.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: February 2, 2021
    Assignee: Quest Diagnostics Investments LLC
    Inventor: Erik P. Johnson
  • Publication number: 20190085376
    Abstract: The present invention provides methods and compositions for determining the presence and/or amount of pathogenic Leptospira in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting pathogenic Leptospira nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Leptospira assay.
    Type: Application
    Filed: April 4, 2016
    Publication date: March 21, 2019
    Applicant: Quest Diagnostics Investiments LLC
    Inventor: Erik P. Johnson
  • Publication number: 20170191116
    Abstract: Described herein are methods for direct detection of microbial agent(s) in a polymicrobial sample, such as a biological sample from a human, without culturing the microbial agent(s). The direct detection can identify mixtures of bacteria and/or fungi in the sample. Also described are primer sequences and amplification techniques for performing the direct detection methods.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 6, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Nik Isely, Jamie L. Platt, Martin Siaw, Ron M. Kagen, Dale A. Schwab
  • Publication number: 20170137867
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Application
    Filed: October 31, 2016
    Publication date: May 18, 2017
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Dale A. Schwab
  • Patent number: 9481914
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 1, 2016
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Dale A. Schwab
  • Publication number: 20160130638
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 12, 2016
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Erik P. Johnson, Dale A. Schwab
  • Patent number: 9200331
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: December 1, 2015
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Erik P. Johnson, Dale A. Schwab
  • Publication number: 20120264126
    Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.
    Type: Application
    Filed: November 17, 2010
    Publication date: October 18, 2012
    Applicant: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Erik P. Johnson, Dale A. Schwab